Gracell Biotechnologies Reports Third Quarter 2021 Unaudited Financial Results and Provides Corporate Update
Gracell Biotechnologies (NASDAQ: GRCL) reported its Q3 2021 financial results, highlighting ongoing advancements in its cell therapy pipeline. Notable developments include progress with the FasTCAR candidate GC012F for multiple myeloma and the TruUCAR candidate GC502 for B-cell malignancies. R&D expenses surged to RMB88.6 million ($13.7 million), reflecting increased activity, while net loss rose to RMB129.3 million ($20.1 million). Cash reserves stood at RMB1,957.5 million ($303.8 million) as of September 30, 2021, bolstered by an IPO that raised approximately $220 million.
- Advancements in FasTCAR candidate GC012F showing promising responses in difficult-to-treat patients.
- Cash reserves of RMB1,957.5 million ($303.8 million) provide a solid financial foundation.
- Successful IPO raised approximately $220 million, enhancing financial stability.
- R&D expenses increased significantly to RMB88.6 million ($13.7 million), indicating rising operational costs.
- Net loss increased to RMB129.3 million ($20.1 million), reflecting ongoing financial challenges.
SUZHOU, China and PALO ALTO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported its unaudited financial results for the third quarter of the year and provided recent business highlights.
“We continue to deliver strong research and clinical execution across our pipeline this quarter, furthering our clinical programs as well as advancing innovative preclinical product candidates to clinical stage,” commented Dr. William (Wei) Cao, founder, Chairman, and CEO of Gracell. “Our autologous and allogeneic T cell therapies are designed to offer differentiated approaches that aim to provide significant improvements in manufacturing, production, efficacy, and cost. We remain focused on building solid clinical foundations across our lead programs, advancing R&D efforts and new preclinical candidates, and enhancing our manufacturing capabilities to provide therapies with reduced cost and increased accessibility to patients.”
“Our lead FasTCAR candidate GC012F, a unique BCMA/CD19 dual-targeting autologous CAR-T cell therapy for the treatment of multiple myeloma developed using the next-day manufacturing FasTCAR platform, has demonstrated fast, deep and durable responses at all dose levels in a predominantly high risk, difficult to treat patient population. We continue advancing with the tech transfer to Lonza to support manufacturing of GC012F in the U.S., an instrumental step towards our US IND filing targeting the first half of 2022. We continue expanding this program including into earlier lines of therapy. GC027, our lead TruUCAR candidate, an off-the-shelf, allogeneic CAR-T cell therapy for the treatment of T-cell malignancies reported encouraging longer-term follow-up data at AACR, and we continue to enroll patients in our ongoing Phase I IIT trial in China for this candidate. We expanded our TruUCAR platform with GC502, a CD19/CD7 dual-directed allogeneic TruUCAR-enabled CAR-T therapy for the treatment of r/r B-ALL and B-NHL recently advancing to clinical stage with the initiation of an IIT study in China. GC502 leverages the unique dual CAR capabilities of the TruUCAR platform, with the CD7 CAR designed to suppress host versus graft rejection, and the second CAR that can have scFv swapped to target different tumor antigens such as CD19, making TruUCAR platform widely applicable. GC502 comprehensively exemplifies the TruUCAR design that aims for optimized persistence without the need of being co-administered with additional immunosuppressive drugs. We look forward to highlighting the preclinical data that lead to advancing this program into the clinic in a poster presentation at ASH 2021. Our donor-derived allogeneic CD19-targeted CAR-T for B-ALL, GC007g, is currently being advanced to the second dose cohort in our pivotal IND Phase 1/2 study in China.”
“We have actively expanded our SMART CART™ solid tumor program, including exploring CLDN18.2 as a target in collaboration with FutureGen, and using preclinical learnings presented at SITC 2021 conference to inform on the optimization of second-generation CAR-T candidates entering clinical stage in the first half of 2022. Gracell’s SMART CART™ technology is designed to incorporate unique cytokine signaling to improve persistence, and reverse and turn immunosuppressive signals of the solid tumor microenvironment into stimulatory reactions of CAR-T cells.”
“Lastly, we will also continue building a strong manufacturing and R&D foundation with the ongoing expansion of our US R&D capabilities and the development of a significantly larger facility for the commercial phase in Suzhou, China in addition to our state-of-the-art, 66,000 sq. ft. GMP manufacturing facility. These clinical, R&D and manufacturing developments will further support our abilities to deliver therapeutic solutions across hematological malignancies and solid tumors that have the potential for optimized cost-efficiency, faster manufacturing, and superior efficacy and safety,” Dr. Cao concluded.
Third Quarter 2021 and Subsequent Highlights
GC502 for the treatment of adult relapsed/refractory B-cell acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma (r/r B-ALL and B-NHL): GC502 is a TruUCAR-enabled CD19/CD7 dual-directed allogeneic CAR-T cell therapy being studied in an ongoing Phase 1 IIT in China for the treatment of adult r/r B-ALL and B-NHL. GC502 is manufactured from T cells of non-human leukocyte antigen (HLA)-matched healthy donors.
- Clinical IIT initiated. IIT study was initiated in China in adult patients with r/r B-ALL and B-NHL.
- Preclinical data presentation at ASH. Preclinical data for GC502 will be featured as a poster presentation at ASH 2021. (Press Release November 2021)
GC007g for the treatment of B-ALL: GC007g is a donor-derived CD19-targeted allogeneic CAR-T cell therapy for the treatment of r/r B-ALL patients who failed transplant and may not be eligible for autologous CAR-T therapy. The allogeneic approach, utilizing T-cells from an HLA-matched healthy donor, has the potential to provide a novel treatment approach to patients not eligible for standard of care.
- Open IND in China and ongoing pivotal Phase 1/2. Pivotal Phase 1/2 clinical study ongoing in China for the treatment of r/r B-ALL patients. (Press Release March 2021).
- Enrolling in second dosing cohort. Successful enrollment of first dosing cohort in the phase 1/2 seamless design study was completed and the study is currently enrolling into second dosing cohort.
SMART CART™ candidates for the treatment of solid tumors: SMART CART™ is our second-generation Enhanced CAR-T platform designed for overcoming tumor microenvironment (TME). SMART CART™ includes altered expression of the receptor and signaling mechanism of an inhibitory TME molecule to enhance CAR-T cell proliferation and persistence, and to reduce exhaustion of CAR-T cells in order to effectively combat solid tumors.
- Favorable clinical IIT data with first generation Enhanced CAR-T. Preliminary clinical IIT data of Gracell’s first generation Enhanced CAR-T for solid tumors has shown tolerability and preliminary efficacy. (Publication August 2021)
- Collaboration with FutureGen. Ongoing collaboration with FutureGen to develop CAR-T therapies targeting Claudin 18.2. (Press Release August 2021)
- Preclinical data presentation at SITC 2021. Preclinical data showing the positive impact of the IL-2 variant on CAR-T functionality and efficacy against solid tumors has been presented as a poster presentation at SITC 2021.
Financial Results for the Third Quarter Ended September 30, 2021
Research and development expenses for the three months ended September 30, 2021 were RMB88.6 million (US
Administrative expenses for the three months ended September 30, 2021 were RMB42.9 million (US
Interest income for the third quarter of 2021 was RMB3.0 million (US
Foreign exchange loss for the three months ended September 30, 2021 was RMB0.8 million (US
Net loss attributable to ordinary shareholders for the three months ended September 30, 2021 was RMB129.3 million (US
Balance Sheet Highlights
As of September 30, 2021, the Company had RMB1,957.5 million (US
The Company early adopted ASU 2016-02, Lease (Topic 842), in the first quarter of 2021. As of September 30, 2021, the Company had operating lease liabilities of RMB36.7 million (US
In the first quarter of 2021, the Company received a payment from the depositary bank in the amount of RMB14.5 million (US
In addition, as of September 30, 2021, the Company had short-term borrowings and current portion of long-term borrowings of RMB58.1 million (US
As of September 30, 2021, 337,496,901 ordinary shares, par value of US
About FasTCAR
CAR-T cells manufactured on Gracell’s proprietary FasTCAR platform appear younger, less exhausted and show enhanced proliferation, persistence, bone marrow migration and tumor cell clearance activities as demonstrated in preclinical studies. With next-day manufacturing, FasTCAR is able to significantly improve cell production efficiency which may result in meaningful cost savings, increasing the accessibility of cell therapies for cancer patients.
About TruUCAR
TruUCAR is Gracell's proprietary technology platform and is designed to generate high-quality allogeneic CAR-T cell therapies that can be administered “off-the-shelf” at lower cost and with greater convenience. With differentiated design enabled by gene editing, TruUCAR is designed to control host vs graft rejection (HvG) as well as graft vs host disease (GvHD) without the need of being co-administered with additional immunosuppressive drugs.
About SMART CART™
SMART CART™ is Gracell's proprietary technology platform designed to further strengthen the functionality of CAR-T cells and aims to overcome tumor microenvironment (TME). SMART CART™ includes altered expression of the receptor and signaling mechanism of an inhibitory TME molecule to increase proliferation and persistence, and to reduce exhaustion of CAR T cells. This design reverses and turns immunosuppressive signals of TME into stimulatory reactions of CAR-T cells. SMART CART™ technology can be applied to many targets for the treatment of solid tumors.
About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR, TruUCAR and SMART CART™ technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com
Follow @GracellBio on LinkedIn
Exchange Rate Information
This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars are made at a rate of RMB 6.4434 to US
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing date of the offering. The words “anticipate,” “look forward to,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the section entitled “Risk Factors” in Gracell’s most recent annual report on Form 20-F as well as discussions of potential risks, uncertainties, and other important factors in Gracell’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Gracell specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.
Media contact
Marvin Tang
marvin.tang@gracellbio.com
Investor contact
Gracie Tong
gracie.tong@gracellbio.com
| Unaudited Condensed Consolidated Balance Sheets | |||||||||
| (All amounts in thousands, except for share and per share data) | |||||||||
| As of December 31, | As of September 30, | ||||||||
| 2020 | 2021 | ||||||||
| RMB | RMB | US$ | |||||||
| ASSETS | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | 754,308 | 1,953,924 | 303,244 | ||||||
| Short-term investments | 18,743 | 3,599 | 559 | ||||||
| Prepayments and other current assets | 42,418 | 60,930 | 9,457 | ||||||
| Total current assets | 815,469 | 2,018,453 | 313,260 | ||||||
| Property, equipment and software | 119,083 | 123,456 | 19,160 | ||||||
| Operating lease right-of-use assets | — | 32,697 | 5,074 | ||||||
| Other non-current assets | 30,398 | 22,238 | 3,451 | ||||||
| TOTAL ASSETS | 964,950 | 2,196,844 | 340,945 | ||||||
| LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ DEFICIT | |||||||||
| Current liabilities: | |||||||||
| Short-term borrowings | 49,990 | 56,090 | 8,705 | ||||||
| Operating lease liabilities, current | — | 17,904 | 2,779 | ||||||
| Current portion of long-term borrowings | 970 | 1,978 | 307 | ||||||
| Accruals and other current liabilities | 42,401 | 61,313 | 9,516 | ||||||
| Total current liabilities | 93,361 | 137,285 | 21,307 | ||||||
| Long-term borrowings | 51,926 | 55,646 | 8,636 | ||||||
| Operating lease liabilities, non-current | — | 18,799 | 2,918 | ||||||
| Other non-current liabilities | — | 9,435 | 1,464 | ||||||
| TOTAL LIABILITIES | 145,287 | 221,165 | 34,325 | ||||||
| Commitments and contingencies | |||||||||
| Mezzanine equity: | |||||||||
| Series A convertible redeemable preferred shares | 110,468 | — | — | ||||||
| Series B-1 convertible redeemable preferred shares | 142,481 | — | — | ||||||
| Series B-2 convertible redeemable preferred shares | 495,799 | — | — | ||||||
| Series C convertible redeemable preferred shares | 658,788 | — | — | ||||||
| Total mezzanine equity | 1,407,536 | — | — | ||||||
| Shareholders’ deficit: | |||||||||
| Ordinary shares | 68 | 223 | 35 | ||||||
| Additional paid-in capital | — | 2,892,354 | 448,886 | ||||||
| Accumulated other comprehensive loss | (23,912 | ) | (27,711 | ) | (4,301 | ) | |||
| Accumulated deficit | (564,029 | ) | (889,187 | ) | (138,000 | ) | |||
| Total shareholders’ deficit | (587,873 | ) | 1,975,679 | 306,620 | |||||
| TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ DEFICIT | 964,950 | 2,196,844 | 340,945 | ||||||
| Unaudited Condensed Consolidated Statements of Comprehensive Loss | ||||||||||||||||||
| (All amounts in thousands, except for share and per share data) | ||||||||||||||||||
| For the three months ended September 30, | For the nine months ended September 30, | |||||||||||||||||
| 2020 | 2021 | 2020 | 2021 | |||||||||||||||
| RMB | RMB | US$ | RMB | RMB | US$ | |||||||||||||
| Revenue | ||||||||||||||||||
| Licensing and collaboration revenue | — | 366 | 57 | — | 366 | 57 | ||||||||||||
| Expenses | ||||||||||||||||||
| Research and development expenses | (39,986 | ) | (88,617 | ) | (13,753 | ) | (108,137 | ) | (219,317 | ) | (34,037 | ) | ||||||
| Administrative expenses | (8,184 | ) | (42,861 | ) | (6,652 | ) | (20,781 | ) | (105,043 | ) | (16,302 | ) | ||||||
| Loss from operations | (48,170 | ) | (131,112 | ) | (20,348 | ) | (128,918 | ) | (323,994 | ) | (50,282 | ) | ||||||
| Interest income | 250 | 2,985 | 463 | 2,416 | 5,651 | 877 | ||||||||||||
| Interest expense | (654 | ) | (1,089 | ) | (169 | ) | (1,350 | ) | (3,736 | ) | (580 | ) | ||||||
| Other income | 220 | 733 | 114 | 1,794 | 866 | 134 | ||||||||||||
| Foreign exchange loss, net | (2,217 | ) | (802 | ) | (124 | ) | (2,237 | ) | (1,903 | ) | (295 | ) | ||||||
| Others, net | 3 | — | — | (12 | ) | (53 | ) | (8 | ) | |||||||||
| Loss before income tax | (50,568 | ) | (129,285 | ) | (20,064 | ) | (128,307 | ) | (323,169 | ) | (50,154 | ) | ||||||
| Income tax expense | — | — | — | — | — | — | ||||||||||||
| Net loss | (50,568 | ) | (129,285 | ) | (20,064 | ) | (128,307 | ) | (323,169 | ) | (50,154 | ) | ||||||
| Accretion of convertible redeemable preferred shares to | ||||||||||||||||||
| redemption value | (18,342 | ) | — | — | (46,392 | ) | (1,989 | ) | (309 | ) | ||||||||
| Net loss attributable to Gracell Biotechnologies Inc.’s | ||||||||||||||||||
| ordinary shareholders | (68,910 | ) | (129,285 | ) | (20,064 | ) | (174,699 | ) | (325,158 | ) | (50,463 | ) | ||||||
| Other comprehensive loss | ||||||||||||||||||
| Foreign currency translation adjustments, net of nil tax | (5,455 | ) | 7,340 | 1,139 | (1,957 | ) | (3,798 | ) | (589 | ) | ||||||||
| Total comprehensive loss attributable to Gracell | ||||||||||||||||||
| Biotechnologies Inc.’s ordinary shareholders | (74,365 | ) | (121,945 | ) | (18,925 | ) | (176,656 | ) | (328,956 | ) | (51,052 | ) | ||||||
| Weighted average number of ordinary shares used in per | ||||||||||||||||||
| share calculation: | ||||||||||||||||||
| —Basic | 99,044,776 | 336,494,609 | 336,494,609 | 99,044,776 | 325,838,207 | 325,838,207 | ||||||||||||
| —Diluted | 99,044,776 | 336,494,609 | 336,494,609 | 99,044,776 | 325,838,207 | 325,838,207 | ||||||||||||
| Net loss per share attributable to Gracell Biotechnologies | ||||||||||||||||||
| Inc.’s ordinary shareholders | ||||||||||||||||||
| —Basic | (0.70 | ) | (0.38 | ) | (0.06 | ) | (1.76 | ) | (1.00 | ) | (0.15 | ) | ||||||
| —Diluted | (0.70 | ) | (0.38 | ) | (0.06 | ) | (1.76 | ) | (1.00 | ) | (0.15 | ) | ||||||
FAQ
What are Gracell Biotechnologies' recent financial results for Q3 2021?
How much cash does Gracell Biotechnologies have as of September 30, 2021?
What is the status of Gracell Biotechnologies' clinical candidates?
What financial milestones did Gracell achieve in its recent IPO?
